Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avadel Pharmaceuticals PLC (ADR) before investing.

In this article, we go over a few key elements for understanding Avadel Pharmaceuticals PLC (ADR)’s stock price such as:

• Avadel Pharmaceuticals PLC (ADR)’s current stock price and volume
• Why Avadel Pharmaceuticals PLC (ADR)’s stock price changed recently
• Upgrades and downgrades for AVDL from analysts
• AVDL’s stock price momentum as measured by its relative strength

About Avadel Pharmaceuticals PLC (ADR) (AVDL)

Before we jump into Avadel Pharmaceuticals PLC (ADR)’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Want to learn more about Avadel Pharmaceuticals PLC (ADR)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avadel Pharmaceuticals PLC (ADR).

Avadel Pharmaceuticals PLC (ADR)’s Stock Price as of Market Close

As of September 11, 2024, 4:00 PM, CST, Avadel Pharmaceuticals PLC (ADR)’s stock price was $13.65.

Avadel Pharmaceuticals PLC (ADR) is down 5.14% from its previous closing price of $14.39.

During the last market session, Avadel Pharmaceuticals PLC (ADR)’s stock traded between $14.00 and $14.53. Currently, there are 96.15 million shares of Avadel Pharmaceuticals PLC (ADR) stock available for purchase.

Unfortunately, Avadel Pharmaceuticals PLC (ADR)’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Avadel Pharmaceuticals PLC (ADR) Stock Price History

Avadel Pharmaceuticals PLC (ADR)’s (AVDL) price is currently down 10.02% so far this month.

During the month of September, Avadel Pharmaceuticals PLC (ADR)’s stock price has reached a high of $15.82 and a low of $13.46.

Over the last year, Avadel Pharmaceuticals PLC (ADR) has hit prices as high as $19.09 and as low as $9.50. Year to date, Avadel Pharmaceuticals PLC (ADR)’s stock is up 90.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Avadel Pharmaceuticals PLC (ADR) Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 10, 2024, there were 3 analysts who downgraded Avadel Pharmaceuticals PLC (ADR)’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Avadel Pharmaceuticals PLC (ADR)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avadel Pharmaceuticals PLC (ADR)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Avadel Pharmaceuticals PLC (ADR)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avadel Pharmaceuticals PLC (ADR) (AVDL) by visiting AAII Stock Evaluator.

Relative Price Strength of Avadel Pharmaceuticals PLC (ADR)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 10, 2024, Avadel Pharmaceuticals PLC (ADR) has a weighted four-quarter relative price strength of -3.26%, which translates to a Momentum Score of 51 and is considered to be Average.

Want to learn more about how Avadel Pharmaceuticals PLC (ADR) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Avadel Pharmaceuticals PLC (ADR) Stock Price: Bottom Line

As of September 11, 2024, Avadel Pharmaceuticals PLC (ADR)’s stock price is $13.65, which is down 5.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avadel Pharmaceuticals PLC (ADR) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.